Decreased expression of dual-specificity phosphatase 9 is associated with poor prognosis in clear cell renal cell carcinoma

BMC Cancer

Volumn 11, Issue 1, 2011, Pages

  Wu, Song ^a,b,c,d   Wang, Yong ^b   Sun, Liang ^b   Zhang, Zhiling ^d   Jiang, Zhimao ^b   Qin, Zike ^d   Han, Hui ^d   Liu, Zhuowei ^d   Li, Xianxin ^b   Tang, Aifa ^a   Gui, Yaoting ^b   Cai, Zhiming ^a,b,c   Zhou, Fangjian ^d  

^a THE FIRST AFFILIATED HOSPITAL OF SHENZHEN UNIVERSITY   (China)

^b Biomedical Research Institute   (China)

^c ANHUI MEDICAL UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DUAL SPECIFICITY PHOSPHATASE; DUSP9 PROTEIN, HUMAN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE;

ADULT; AGED; ARTICLE; CANCER STAGING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS;

ADULT; AGED; CARCINOMA, RENAL CELL; DUAL-SPECIFICITY PHOSPHATASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASES; NEOPLASM STAGING; PROGNOSIS; RNA, MESSENGER;

EID: 80053362152     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-413     Document Type: Article

References (25)

1. McLaughlin JK, Lipworth L, Tarone RE Epidemiologic aspects of renal cell carcinoma. Semin Oncol 2006, 33:527-523.
2. Motzer RJ, Bander NH, Nanus DM Renal-cell carcinoma. N Engl J Med 1996, 335:865-875.
3. Janzen NK, Kim HL, Figlin RA, Belldegrun AS Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003, 30:843-852.
4. Christie GR, Williams DJ, Macisaac F, Dickinson RJ, Rosewell I, Keyse SM The dual-specificity protein phosphatase DUSP9/MKP-4 is essential for placental function but is not required for normal embryonic development. Mol Cell Biol 2005, 25:832-833.
5. Lewis TS, Shapiro PS, Ahn NG Signal transduction through MAP kinase cascades. Adv Cancer Res 1998, 74:49-139.
6. Liu Y, Lagowski J, Sundholm A, Sundberg A, Kulesz-Martin M Microtubule disruption and tumor suppression by mitogen-activated protein kinase phosphatase 4. Cancer Res 2007, 67:10711-10719.
7. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande Woude GF, Ahn NG Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 1994, 265:966-970.
8. Zhou L, Chen J, Li Z, Li X, Hu X, Huang Y, Zhao X, Liang C, Wang Y, Sun L, Shi M, Xu X, Shen F, Chen M, Han Z, Peng Z, Zhai Q, Chen J, Zhang Z, Yang R, Ye J, Guan Z, Yang H, Gui Y, Wang J, Cai Z, Zhang X Integrated Profiling of MicroRNAs and mRNAs: MicroRNAs Located on Xq27.3 Associate with Clear Cell Renal Cell Carcinoma. PLoS ONE 2010, 5:e15224.
9. Greene FL, Balch CM, Fleming ID, Fritz A, Haller DG, Morrom M, David L, AJCC: Cancer Staging Manual. New York: AJCC Springer-Verlag;, 6 2002, 335-340.
10. Tsuchiya A, Sakamoto M, Yasuda J, Chuma M, Ohta T, Ohki M, Yasugi T, Taketani Y, Hirohashi S: Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 2003, 163:2503-2512.
11. Saussez S, Cucu DR, Decaestecker C, Chevalier D, Kaltner H, André S, Wacreniez A, Toubeau G, Camby I, Gabius HJ, Kiss R Galectin 7 (p53-induced gene 1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer. Ann Surg Oncol 2006, 13:999-1009.
12. Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu M, Shao R, Anderson RM, Rich JN, Wang XF Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 2004, 5:329-339.
13. Chow WH, Dong LM, Devesa SS Epidemiology and risk factors for kidney cancer. Nat Rev Urol 2010, 7:245-257.
14. McCredie M Bladder and kidney cancers. Cancer Surv 1994, 19:343-368.
15. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF, Sinescu IC European Association of Urology Guideline Group:EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010, 58:398-406.
16. Sabatino M, Kim-Schulze S, Panelli MC, Stroncek D, Wang E, Taback B, Kim DW, Deraffele G, Pos Z, Marincola FM, Kaufman HL Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 2009, 27:2645-2652.
17. Banks RE, Craven RA, Harnden P, Madaan S, Joyce A, Selby PJ Key clinical issues in renal cancer: a challenge for proteomics. World J Urol 2007, 25:537-556.
18. Brondello JM, Brunet A, Pouyssegur J, McKenzie FR The dual specificity mitogen-activated protein kinase phosphatase-1 and -2 are induced by the p42/p44MAPK cascade. J Biol Chem 1997, 272:1368-1376.
19. Keyse SM Protein phosphatases and the regulation of mitogen-activated protein kinase signalling. Curr Opin Cell Biol 2000, 12:186-192.
20. Sun H, Tonks NK, Bar-Sagi D Inhibition of Ras induced DNA synthesis by expression of the phosphatase MKP-1. Science 1994, 266:285.
21. Liao Q, Guo J, KleeffJ, Zimmermann A, Büchler MW, Korc M, Friess H Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumor-igenicity of pancreatic cancer cells. Gastroenterology 2003, 124:1830-1845.
22. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362.
23. Zhang Z, Li J, Zheng H, Yu C, Chen J, Liu Z, Li M, Zeng M, Zhou F, Song L Expression and cytoplasmic localization of SAM68 is a significant and independent prognostic marker for renal cell carcinoma. Cancer Epidemiol Biomarkers Prev 2009, 18:2685-2693.
24. Buchner A, Castro M, Hennig A, Popp T, Assmann G, Stief CG, Zimmermann W Down-regulation of HNF-1B in renal cell carcinoma is associated with tumor progression and poor prognosis. Urology 2010, 76: e6-11.
25. Levi F, Ferlay J, Galeone C, Lucchini F, Negri E, Boyle P, La Vecchia C The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int 2008, 101:949-958.